Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Effect of Passive Immunization on the Progression of Alzheimer's Disease: LY2062430 Versus Placebo

Next Previous
Trial Profile

Effect of Passive Immunization on the Progression of Alzheimer's Disease: LY2062430 Versus Placebo

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 15 Oct 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Solanezumab (Primary) ; Florbetapir F 18
  • Indications Alzheimer's disease
  • Focus Registrational; Therapeutic Use
  • Acronyms EXPEDITION-2
  • Sponsors Eli Lilly and Company

    • Most Recent Events

    • 30 Jul 2021 Results from ENGAGE, EMERGE, Expedition 1, 2, and 3 and the PRIME study; combining evidence across outcomes and trials using bayesian hierarchical analysis, presented at the Alzheimer's Association International Conference 2021
    • 31 Jul 2020 Results of post hoc analysis from EXPEDITION-1 and EXPEDITION-2 presented at the Alzheimer's Association International Conference 2020
    • 20 Jul 2017 Results of PK/PD model development and evaluation using patient data from NCT00905372, NCT00904683, NCT01900665 trials presented at the Alzheimer's Association International Conference 2017
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top